FINNENCE ▪ THE WIRE FILE
THE WIRE · № 81926
News■ Unclear/unknown
Brii Biosciences Unveils BRiSC™, an siRNA Therapeutics Discovery Platform
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Early-stage siRNA discovery platform; preclinical, no revenue or trial data.
Early siRNA platform, long path to monetization
CATALYST TO WATCH
First development candidate nomination
MAIN RISK
Preclinical stage, high failure probability
FULL DISPATCH
Proprietary BRiSC™ platform to advance the discovery and development of next-generation dual-targeting siRNA medicines Initial focus on prevalent metabolic dysfunctions where complex disease biology and overlapping comorbidities will benefit from coordinated modulation of multiple...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer2026-10-15 11:30 UTC
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer2026-10-15 11:30 UTC
→CORRELATIONshares Healthcare
OrbiMed lève 3 milliards de dollars auprès de fonds de capital-investissement mondiaux et asiatiques.2026-10-15 11:30 UTC
OrbiMed lève 3 milliards de dollars auprès de fonds de capital-investissement mondiaux et asiatiques.2026-10-15 11:30 UTC
→CORRELATIONshares Healthcare
OrbiMed Raises $3 Billion Across Global and Asia Private Equity Funds2026-10-15 11:30 UTC
OrbiMed Raises $3 Billion Across Global and Asia Private Equity Funds2026-10-15 11:30 UTC
→CORRELATIONshares Healthcare
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health2026-10-15 11:30 UTC
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health2026-10-15 11:30 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
New Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC2026-10-15 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
New Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.2026-10-15 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.